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Background: Colorectal cancer-specific biomarkers have been used as molecular targets for fluorescent intra-operative imaging,
targeted PET/MRI, and selective cytotoxic drug delivery yet the selection of biomarkers used is rarely evidence-based. We
evaluated sensitivities and specificites of four of the most commonly used markers: carcinoembryonic antigen (CEA), tumour-
associated glycoprotein-72 (TAG-72), folate receptor-a (FRa) and Epithelial growth factor receptor (EGFR).
Methods: Marker expression was evaluated semi-quantitatively in matched mucosal and colorectal cancer tissues from 280
patients using immunohistochemistry (scores of 0–15). Matched positive and negative lymph nodes from 18 patients were also
examined.
Results:Markers were more highly expressed in tumour tissue than in matched normal tissue in 98.8%, 79.0%, 37.1% and 32.8% of
cases for CEA, TAG-72, FRa and EGFR, respectively. Carcinoembryonic antigen showed the greatest differential expression, with
tumours scoring a mean of 10.8 points higher than normal tissues (95% CI 10.31–11.21, Po0.001). Similarly, CEA showed the
greatest differential expression between positive and negative lymph nodes. Receiver operating characteristic analyses showed
CEA to have the best sensitivity (93.7%) and specificity (96.1%) for colorectal cancer detection.
Conclusion: Carcinoembryonic antigen has the greatest potential to allow highly specific tumour imaging and drug delivery;
future translational research should aim to exploit this.
There is much interest in developing strategies for tumour-specific
delivery of agents to increase our diagnostic capability or enhance
the selectivity and effectiveness of therapeutics. These strategies
rely on the ability to target tumour cells accurately using
biomarkers that are differentially expressed between tumour and
normal tissue. In colorectal cancer, the most commonly used
biomarkers include carcinoembryonic antigen (CEA) (Muguruma
et al, 1999; Sharkey et al, 2005; Kaushal et al, 2008; Yazaki and
Kassa et al 2008; Heine et al, 2011), tumour-associated glycopro-
tein-72 (TAG-72) (Tang et al, 2007; Chen et al, 2008; Zou et al,
2009; Chen et al, 2011), Epithelial growth factor receptor (EGFR)
(Goetz et al, 2010; Jeong et al, 2012; Qi et al, 2012), and folate
receptor-a (FRa) (Reddy and Low, 1998; Chen et al, 2005; Yang
et al, 2010). Carcinoembryonic antigen and TAG-72 are mem-
brane-bound glycoproteins that are expressed in over 80% of
colorectal cancers with relatively little expression in normal
mucosa (Johnson et al, 1986; Jantscheff et al, 2003). Folate
receptor-a is a membrane-bound protein that binds and transports
folic acid and is overexpressed in epithelial-derived cancers,
including those of the colorectum (Shia et al, 2008). It appears to
be expressed relatively infrequently in colorectal tumours but is
absent in the vast majority of normal tissues, hinting at a
potentially high specificity (Shia et al, 2008). Epithelial growth
factor receptor is a well-known target for anti-cancer therapies but
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the literature concerning the degree and frequency of EGFR
overexpression in colorectal cancer is contradictory, with reported
expression varying from 33% to 97% of cases (Koretz et al, 1990;
Lee et al, 2002; Spano et al, 2005; Bhargava et al, 2006). It is also
reported to be expressed in up to 48% of normal colorectal samples
(Koretz et al, 1990), which could compromise its specificity for
cancer tissue.
Identification of biomarkers that are sensitive and specific for
colorectal cancer opens up many avenues for diagnostic and
therapeutic exploitation. The ability to visualise tumours and their
metastases during surgery may facilitate more accurate and
disease-specific operations. Fluorescence-based, laparoscopic ima-
ging, using antibodies targeting antigens found on tumour cells,
has already shown considerable potential (Mahmood, 2010;
Tiernan et al, 2012). In non-invasive imaging, iodine-124 labelled
antibodies to CEA have been administered to enhance PET cancer
scanning (Schoffelen et al, 2010; Boerman and Oyen, 2011;
Carrasquillo et al, 2011; Meller et al, 2011; O’Donoghue et al, 2011;
Schoffelen et al, 2012), and CEA antibodies have been conjugated
to iron oxide nanoparticles to improve MRI imaging (Vigour et al,
2010). In therapeutic applications, radioisotope antibodies, usually
directed towards CEA or TAG-72, have been used to deliver
tumour selective radiotherapy (Meredith et al, 1996; Meyer et al,
2009; de Jong et al, 2011) and have been shown to be particularly
effective in small-volume disease (Koppe et al, 2005; Barbet et al,
2012). Similarly, targeted cytotoxic drug delivery has the potential
to deliver high-dose chemotherapy to cancer cells, while limiting
damage to normal cells, and has utilised a variety of biomarkers,
including FRa (Li et al, 2011; Zhang et al, 2012), EGFR (Kopansky
et al, 2011) and CEA (Conaghan et al, 2008).
A surprising feature of all the above examples of targeted
tumour delivery is that the choice of biomarker used is rarely
justified in terms of its tumour sensitivity and specificity. The
characteristics of suitable cancer biomarkers are that they must be
highly expressed in a large majority of tumours and have low or no
expression in normal tissue, encompassing the normal tissue from
which the tumour is derived and – ideally – most or all normal
adult tissues accessible to systemic delivery. Suitable molecules
must also be located on the external facing surfaces of cancer cells
so as to be accessible to systemically delivered recognition
molecules. To our knowledge, expression of the most commonly
used markers for colorectal cancer has never been rigorously
evaluated in a well-defined cohort of cancer and normal tissue. We
aimed to evaluate the sensitivity and specificity of the four most
commonly used markers for colorectal cancer, CEA, TAG-72, FRa,
and EGFR, to define which is most suitable for in vivo tumour
targeting.
MATERIALS AND METHODS
Ethical issues and patient cohort. Ethical approval was obtained
from the National Research Ethics Service (London-Dulwich
Committee), reference 12/LO/1327. Formalin-fixed paraffin-
embedded tissue blocks containing primary colorectal carcinoma
and matched normal colorectal mucosa, collected prospectively for
the MRC CLASICC trial (Guillou et al, 2005), were available from
280 patients. Table 1 shows patient and tumour characteristics.
Formalin-fixed paraffin-embedded blocks containing mesenteric
lymph nodes (both tumour cell positive and negative) were
available for 18 of the patients.
Antibodies and immunohistochemistry. Antibody suppliers and
evidence for antibody specificity are described below. A5B7
humanised anti-CEA antibody was supplied by the Cancer
Research UK Biotherapeutics Development Unit (Clare Hall
Laboratories, UK) and has been used in clinical trials of targeted
therapies (Dawson et al, 1991; Meyer et al, 2009). Mouse anti-
TAG-72 antibody (clone CC49; Santa Cruz, CA, USA) has been
used widely to target colorectal cancer in radioimmunoguided
surgery (Sun et al, 2007; Povoski et al, 2012). Mouse anti-EGFR
antibody (clone 31G7; Invitrogen, Carlsbad, CA, USA) has been
shown to be highly sensitive in detection of EGFR positive
colorectal tumours (Buckley and Kakar, 2007). Mouse anti-FR-a
antibody (clone BN3.2; Leica Biosystems, Newcastle, UK) has been
validated across a wide range of tissues, including colorectal tissue
(Smith et al, 2007). Antibodies were optimised for use in
immunohistochemistry on whole colorectal cancer tissue sections
to give a broad range of epithelial staining intensities with minimal
background staining. Tissue microarrays were constructed from
formalin-fixed paraffin-embedded resection samples of colorectal
cancer and matched normal colorectal mucosa using 0.6-mm
cores. For each patient, three cores were selected from the most
representative tumour area (as determined by haematoxylin and
eosin staining) and three cores from normal mucosa. Tissue
microarray blocks or lymph nodes blocks were sectioned onto
SuperFrost Plus microscope slides (Menzel-Glaser, Braunschweig,
Germany), dewaxed with xylene and rehydrated through ethanol
before rinsing in water for 5min. Epitopes were retrieved either by
heating slides in pre-warmed 10mM citric acid buffer (pH 6.0,
microwave 900W, 10min; anti-CEA and anti-TAG-72), using a
pressure cooker (anti-FRa), or incubating in proteinase K (25min,
37 1C; anti-EGFR). Endogenous peroxidase activity was blocked
with 0.6% hydrogen peroxide for 10min before rinsing in water for
5min. Slides were mounted in Sequenzas (Thermo Scientific,
Waltham, MA, USA) and rinsed with tris-buffered saline (TBS)
followed by antibody diluent reagent solution (Invitrogen).
Primary antibodies were used in diluent reagent at 1 : 100,
1 : 150 000, 1 : 25, 1 : 50 and 1 : 50 for anti-TAG-72, anti-CEA,
anti-FRa, and anti-EGFR, respectively. Incubations were at room
temperature for 1 h (CEA, TAG-72) or overnight at 4 1C (FRa,
EGFR). Slides were washed twice with TBS-T (TBS, 10% Tween
20) and once with TBS before incubating with an appropriate
horseradish peroxidise conjugated secondary antibody (Dako,
Glostrup, Denmark) for 30min at room temperature. The slides
were washed with TBS-T and TBS. 100 ml of 3,30-diaminobenzi-
dene (Dako) solution was added to each slide for 10min before a 5-
min wash in water. Slides were then stained with haematoxylin,
dehydrated with ethanol and xylene, and mounted with DPX
Histology mountant (Fluka, St. Louis, MO, USA).
Scoring and statistical analyses. Slides were digitally scanned
using Scanscope XT (Aperio, Vista, CA, USA) at 20 magnifica-
tion and were observed for scoring using ImageScope v11 (Aperio).
Staining was assessed semi-quantitatively using a bespoke scoring
Table 1. Clinico–pathological details of patient cohort
Characteristics Number of cases (%) n¼280
Age range: 33–93 years
Mean age: 68.9 years
Male 144 (51.4)
Female 136 (48.6)
pT stage
1 10 (3.6)
2 54 (19.3)
3 161 (57.5)
4 52 (18.6)
Unknown 3 (1.1)
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system developed in consultation with two pathologists (ETV and
NPW). Cores were scored for intensity of epithelial cell staining (0,
no staining; 1, mild; 2, moderate; 3, strong) and percentage of
epithelial cells staining positively (0,o5%; 1, 5–20%; 2, 21–40%; 3,
41–60%; 4, 61–80%; 5, 81–100%). These scores were multiplied to
give final scores of 0–15. Tumour cores with no tumour cells and
normal cores with no epithelial cells visible were discounted.
Carcinoembryonic antigen and TAG-72 were scored for apical
membranous staining only. Folate receptor-a showed mild
cytoplasmic staining only, and was scored solely for this. Epithelial
growth factor receptor showed membranous, and – more rarely –
cytoplasmic and nuclear staining. However, following established
literature (Scartozzi et al, 2004; Buckley and Kakar, 2007) EGFR
was scored for membranous expression only. Two independent
observers were involved in the scoring: JPT scored all cores and
ETV scored cores representing 15% of the cases. Scoring
reproducibility was determined for each antibody using the
intra-class correlation coefficient; the process of calculating the
mean score for each patient led to 61 possible outcomes, and
therefore the data were treated as continuous rather than
categorical. Scores for each case of tumour or normal tissue were
means of scores allocated by JPT for each core from that tissue. If
only one core score was available, for example owing to lack of
appropriate cell types or core loss, this single score was used; a
method that has been validated previously (Camp et al, 2000;
Torhorst et al, 2001)). Means for normal and tumour tissue were
compared using Wilcoxon signed-rank tests for paired non-
parametric data. Sensitivities and specificities were calculated from
the mean scores for tumour and normal tissue expression for each
case using two different cutoff points: the 95th percentile of the
normal tissue score distribution and optimal cutoffs identified by
receiver operating characteristic curves (Maraqa et al, 2008).
RESULTS
Expression of markers in normal colorectal tissue and tumours.
We examined expression of CEA, TAG-72, FRa and EGFR in a
cohort of 280 colorectal carcinomas and matched normal tissues.
Clinical and pathological features of this cohort are shown in
Table 1. Representative images of staining for each antigen in both
normal and tumour tissues are shown in Figure 1. All four markers
showed epithelial cell specific staining that was diffuse with some
luminal accentuation. No staining for any marker was noted in
blood cells within the sections, suggesting that expression in this
compartment is negligible. The intra-class correlation coefficient
was 0.89, demonstrating good agreement between scorers. Both the
proportion of epithelial cells staining positively and the intensity of
staining varied widely throughout the cohort in normal and
tumour tissues (Figure 2). Strongly positive staining in normal
tissues was relatively uncommon for all antigens, especially for FRa
(negative in over 99% at the concentrations used). In the tumours,
by contrast, strongly positive staining was prevalent for CEA and
TAG-72, and was more common for FRa than in normal tissue
although tumours were also mostly negative (61%). Epithelial
growth factor receptor staining in tumours showed a similar range
of scores to those in normal tissues. Carcinoembryonic antigen,
TAG-72 and FRa, but not EGFR, were significantly more highly
expressed in colorectal tumour tissues than in the normal tissues
(Po0.001; Table 2).
Differential expression between matched normal and tumour
tissue. If markers are to be used for tumour-specific imaging or
therapeutic delivery, the frequency and the magnitude of increased
expression in tumours are key parameters. Expression scores were
higher in tumours as compared with matched normal tissues in
98.8%, 79.0%, 37.1% and 32.8% of cases for CEA, TAG-72, FRa
and EGFR, respectively. Although this percentage is relatively low
for FRa it should be noted that expression was higher in tumours
as compared with matched normal tissue in almost all cases where
positive staining was detected in either tissue. However, in the case
of EGFR, expression was higher in normal tissue (34% of cases)
more frequently than in tumours (33% of cases), indicating little or
no bias for tumour-specific expression. We have estimated the
magnitude of the differences in expression between matched
tumour and normal tissues as the tumour expression score minus
the normal expression score (Figure 3). Carcinoembryonic antigen
demonstrated the greatest difference in expression, with tumours
scoring on average 10.8 (95% CI 10.31–11.21) points higher than
normal tissues. This difference was more than twice that of the
next best marker, TAG-72, which showed tumour expression 5.1
(95% CI 4.35–5.77) points higher than normal tissue, while FRa
and EGFR showed only very small increases in expression within
the tumours.
Expression of markers in lymph nodes. If markers are to be used
for imaging or therapeutic targeting of tumour deposits within
CEA TAG-72 EGFR FR
Figure 1. Representative tissue microarray cores of normal colorectal tissue (top row) and colorectal tumours (bottom row) showing immuno-
reactivity as labelled. The normal tissue cores shown demonstrate the median score for that antigen in normal colorectal tissues (CEA¼ 1; TAG-
72¼ 2; EGFR¼0; FRa¼ 0). The tumour cores shown demonstrate the median positive score for that antigen in colorectal tumours (CEA¼15; TAG-
72¼ 10; EGFR¼2; FRa¼1). Scale bar¼100mm.
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lymph nodes, marker expression both of tumour cells in tumour-
cell positive lymph nodes and of normal lymph node tissues are
critical. We examined expression of the four markers in lymph
nodes taken during resection from 18 of the patients from our
cohort. In each case, we examined a node found to contain
metastatic tumour cells (‘positive’) and a node that was clear of
metastatic deposits (‘negative’) (Figure 4). Expression of all
markers was uncommon in negative nodes; TAG-72 showed the
most staining, being expressed at only low levels by cells in the
germinal centres in 5 out of 18 cases. The distributions of
expression in positive nodes were similar to the patterns seen in
primary tumours, with prevalent and strong expression of CEA
and TAG-72, and less frequent and weaker expression of FRa
and EGFR.
Specificity and sensitivity of markers for tumour detection.
Accurate imaging of tumours based on the expression of any
marker is heavily influenced by the limit of detection of the
imaging system for marker expression. We have modelled this
influence for each marker by examining what proportion of
tumours would be successfully visualised when different expression
scores were defined as the limit of detection; this is the sensitivity.
We have also tested what proportion of normal tissues would be
‘invisible’, as required for tumour-specific imaging, using the same
limits; this is the specificity. First, we arbitrarily set this cutoff point
as the 95th percentile of the normal score distribution, thereby
tolerating a 5% chance of incorrectly detecting normal tissue as
positive (a specificity of 95%). This cutoff gave sensitivities of
93.7%, 45.4%, 39.3% and 11.8% for CEA, TAG-72, FRa and EGFR,
respectively. We then plotted a ROC curve for each marker
(Supplementary Figure S1) and used these to select the cutoff
scores that gave the greatest combined sensitivity and specificity.
These cutoff scores gave sensitivities and specificities of 93.7% and
96.1% for CEA, 70.3% and 78.5% for TAG-72, 39.3% and 99.2% for
FRa, and 21.7% and 90.5% for EGFR.
DISCUSSION
In vivo tumour-specific targeting is a central requirement of many
novel diagnostic and therapeutic strategies being developed for
cancer. In colorectal cancer, the ability to detect and stage cancers
intra-operatively has the potential to improve patient outcomes by
accurate determination of resection margins and assessment of
disease dissemination. Similarly, tumour-specific delivery of
cytotoxic drugs or contrast agents for enhanced imaging has the
potential to improve adjuvant treatment and diagnosis, respec-
tively. Experimental work to date has relied mainly on antibodies
directed at cell membrane proteins, such as CEA, TAG-72, FRa or
EGFR (Reddy and Low, 1998; Muguruma et al, 1999; Zou et al,
2009; Goetz et al, 2010), although the field is advancing with the
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Figure 2. Expression levels of CEA, TAG-72, EGFR or FRa in normal
colorectal tissue (left) and in colorectal tumours (right). Expression
levels were determined in 280 matched normal and tumour tissues by
immunohistochemistry using semi-quantitative scores of 0–15. The
scores for each marker are arranged independently in ascending order
to demonstrate the distributions across the cohort.
Table 2. CEA, TAG-72 and FRa are significantly more highly expressed in
colorectal tumour tissue than matched normal tissue
Antigen Mean normal score Mean tumour score P-value
CEA 1.7 12.4 o0.001
TAG-72 2.7 7.8 o0.001
FRa 0.0 0.7 o0.001
EGFR 0.9 1.3 0.08
Abbreviations: CEA¼ carcinoembryonic antigen; EGFR¼Epithelial growth factor receptor;
FRa¼ folate receptor-a; TAG-72¼ tumour-associated glycoprotein-72.
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Figure 3. Carcinoembryonic antigen shows the most consistent
overexpression in tumour tissues and the greatest differential
expression between matched normal and tumour tissues. Left:
Expression scores for normal tissues were subtracted from those for
matched tumour tissues to quantify the degree of tumour
overexpression for each case. Overexpression scores for each marker
are arranged in ascending order to demonstrate the distributions
across the cohort (left). Minus scores reflect cases where tumour
expression was lower than expression in the matched normal tissue.
Mean overexpression scores (central marker) with 95% confidence
intervals (error bars) are also shown (right).
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Figure 4. Expression levels of CEA, TAG-72, EGFR or FRa in lymph
nodes, containing colorectal tumour deposits (‘positive’; right) and in
matched lymph nodes lacking tumour cells (‘negative’; left). Expression
levels were determined by immunohistochemistry using scores of 0–15
in 18 cases. The scores for each marker are arranged independently in
ascending order to demonstrate the distributions across the cohort
(note: datapoints are linked by lines to aid interpretation of the
distributions not to imply adjacent datapoints are directly related).
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introduction of aptamer-based approaches. Surprisingly, given the
dependency on accurate biomarker localisation, the selection of the
markers used for tumour targeting is rarely justified based on their
sensitivity or specificity. One would not contemplate using a
marker giving poor specificity and sensitivity in routine laboratory
analysis, and the same stringent criteria should therefore apply to
in vivo tumour identification.
We examined the expression of four most commonly used
colorectal cancer biomarkers in a large cohort of matched normal
and tumour tissue using immunohistochemistry to determine their
potential suitability for in vivo diagnostic and therapeutic
application. Markers proving unsuitable in this analysis would
most likely have no potential utility for the in vivo applications,
which are even further limited by additional variables, such as
tissue penetration, immunological response, and expression of
markers within other normal tissues. To make our assessment we
investigated three key criteria: (i) the proportion of the cohort in
which tumours stained positively for markers, (ii) the proportion
of the cohort in which tumours stained more strongly for markers
than the matched normal tissues, and (iii) the magnitude of
overexpression in tumours. Carcinoembryonic antigen out-per-
formed other markers dramatically in all three measures, showing
the most frequent tumour expression, and the most frequent and
greatest tumour overexpression (Figures 2 and 3). In particular,
differential CEA expression within normal/tumour pairs was
notably greater as compared with other markers, providing
evidence that CEA is the most reliable marker for differentiating
between normal and tumour tissue. In the context of lymph nodes,
CEA was again the superior target, with high levels and frequency
of expression within positive nodes, and only minimal expression
in normal lymph node tissue (Figure 4).
In practical imaging situations, the threshold, or cutoff, used to
differentiate between normal and tumour would be determined by
the user, by adjusting the signal gain. This could be altered to
favour either sensitivity (lowering the cutoff to detect tumours
more easily at the risk of detecting normal tissue erroneously) or
specificity (raising the cutoff to avoid detection of normal tissue at
the risk of missing tumour cells). We quantified the abilities of the
markers to be used in tumour cell detection using their optimal
cutoffs, as determined using ROC analyses, in terms of sensitivity
(proportion of tumours correctly detected) and specificity
(proportion of normal tissues correctly not detected). Carcinoem-
bryonic antigen was the most sensitive marker by a considerable
margin (93.7%, as compared with the nearest alternative TAG-72
at 70.3%), and was also highly specific (96.1%). Folate receptor-a
was the most specific marker (99.2%); however, its utility is limited
by the fact that it was not detectable in the majority of tumours, as
previously reported (Shia et al, 2008), resulting in a poor sensitivity
(39.3%). In addition, the magnitude of differential expression
between normal and tumour was relatively narrow, providing less
security in determining tumour or normal identities. Most notably,
EGFR was a surprisingly poor marker, being detected in less than
half the tumours and being commonly more highly expressed in
normal tissues than in tumours. For applications aiming at targeted
delivery of therapeutics, similar considerations apply. Markers
must allow a balance between ensuring tumour cells receive the
cytotoxic insult while minimising collateral damage in normal cells
that may express the antigen. In this context, FRa may be an
appropriate target in the tumours that express it, with very high
specificity allowing minimal damage to normal cells. However,
CEA is more suitable in a much larger proportion of tumours,
accepting that normal tissues may suffer some dose of drug, albeit a
much lower dose than the tumour cells.
We therefore conclude that of the four biomarkers tested, CEA
alone is the most suitable for tumour targeting, and this should be
reflected in future strategies for in vivo tumour diagnosis and
therapeutic delivery.
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